Abstract: Provided herein are peptides and nanoparticles conjugates thereof useful for the treatment of diseases and disorders mediated by GIPC/synectin, such as cancer.
Type:
Grant
Filed:
October 23, 2013
Date of Patent:
October 20, 2015
Assignees:
Trustees of Darmouth College, Mayo Foundation for Medical Education and Research
Inventors:
Debabrata Mukhopadhyay, Priyabrata Mukherjee, Mark Spaller
Abstract: Embodiments are directed to a method, a computer readable medium encoded with instructions that, when executed, perform a method, and a system for performing mass spectrometry analysis. Molecules of different samples may be labeled with a chemical tag, allowing a multiplexed analysis of multiple samples. The labeled molecules may be fragmented, each fragmented molecule creating at least two separate ions. The relative abundance of each of the heavier ions, which may comprise the original molecule from the sample, may be measured. A relative abundance of the labeled molecules in each of the samples may be determined from the measured relative abundances of the heavier ions.
Type:
Application
Filed:
October 22, 2013
Publication date:
October 15, 2015
Applicant:
President and Fellows of Harvard College
Inventors:
Martin Helmut Wuhr, Steven P. Gygi, Wilhelm Haas, Graeme Conrad McAlister, Leonid Peshkin, Ramin Rad, Marc W. Kirschner
Abstract: The invention concerns a prognostic method for determining at least one, or a combination, of the following: time to first treatment, response to treatment or overall survival for a patient presenting with a disease including or characterised by telomere shortening, comprising an assessment of the longest mean telomere length at which telomere end-end fusion events can be detected and then a determination of the mean telomere length in the fusogenic range (i.e. the range below said mean telomere length at which telomere end-end fusion events can be detected) and the subsequent use of the mean telomere length in the fusogenic range as a prognostic indicator.
Type:
Application
Filed:
August 9, 2012
Publication date:
October 15, 2015
Applicant:
University College Cardiff Consultants Limited
Inventors:
Duncan Baird, Chris Pepper, Christopher Fegan
Abstract: Certain embodiments disclosed herein are directed to a method of producing pancreatic cells or pancreatic cell precursors by exposing human embryonic stem cells to an effective amount of at least one compound listed in Table I to differentiate the human embryonic stem cells into the pancreatic cells or the pancreatic cell precursors. Kits and pancreatic cell lines produced using the methods are also described.
Type:
Grant
Filed:
May 20, 2014
Date of Patent:
October 13, 2015
Assignee:
President and Fellows of Harvard College
Inventors:
Shuibing C. Chen, Douglas A. Melton, Malgorzata Borowiak, Julia Lamenzo Fox, Stuart L. Schreiber, Lee F. Peng, Lance Davidow, Kelvin Lam, Lee L Rubin
Abstract: The invention is based on the surprising finding that treatment with a chemotherapeutic agent such as 5-fluorouracil (5-FU) and an autophagy inducer effectively inhibit the continued growth of, and prevent the recovery following drug withdrawal, of cancer cells. In vivo, drug resistance from a failure to adequately engage in apoptotic programmed cell death leads to a recurrence of cancer and tumors can remain dormant for periods of time before re-emerging as drug resistant metastases. It has been hypothesized that autophagy (Type II cell death) may help cancer cells survive in response to growth limiting conditions, such as nutrient depletion, hypoxia, absence of growth factor, or presence of cytotoxic drug. LiCl is a known autophagy inducer and accelerates cell survival to autophagic programmed cell death.
Type:
Grant
Filed:
March 5, 2013
Date of Patent:
October 13, 2015
Assignee:
University of College Cork, National University of Ireland
Inventors:
Sharon McKenna, Gerald C. O'Sullivan, Tracey O'Donovan
Abstract: The present invention generally relates to multiple emulsions, and to methods and apparatuses for making multiple emulsions. A multiple emulsion generally describes larger droplets that contain one or more smaller droplets therein. The larger droplets may be suspended in a third fluid in some cases. These can be useful for encapsulating species such as pharmaceutical agents, cells, chemicals, or the like. In some cases, one or more of the droplets can change form, for instance, to become solidified to form a microcapsule, a liposome, a polymerosome, or a colloidosome. Multiple emulsions can be formed in one step in certain embodiments, with generally precise repeatability, and can be tailored to include one, two, three, or more inner droplets within a single outer droplet (which droplets may all be nested in some cases).
Type:
Application
Filed:
April 8, 2015
Publication date:
October 8, 2015
Applicant:
President and Fellows of Harvard College
Inventors:
David A. Weitz, Darren Roy Link, Andrew S. Utada
Abstract: The invention provides methods, cells and constructs for optical measurement of membrane potential. These methods can be used in cells that are not accessible to presently available methods using electrodes. The methods can be directed to, for example, high-throughput drug screening assays to determine agents that can affect membrane potential of a target cell.
Type:
Application
Filed:
June 15, 2015
Publication date:
October 8, 2015
Applicant:
President and Fellows of Harvard College
Inventors:
Adam E. Cohen, Joel Kralj, Adam D. Douglass
Abstract: The invention relates to ?-catenin targeting peptides comprising an ?-helical segment that are optionally stapled or stitched, and pharmaceutical compositions thereof. Uses of the inventive ?-catenin targeting polypeptides including methods for treatment of disease, such as diseases associated with aberrant Wnt signaling, including cancer, are also provided.
Type:
Application
Filed:
February 5, 2015
Publication date:
October 8, 2015
Applicant:
President and Fellows of Harvard College
Inventors:
Gregory L. Verdine, Tom N. Grossmann, Tsung-Han Johannes Yeh
Abstract: A semiconductor lasing device (10) for emitting radiation at multiple distinct wavelengths, the device (10) comprising an active layer (16) having first portion (20) and a second portion (21), the first and second portions (20, 21) being separated by a Bragg grating (19) extending through the entire depth of the active layer (16), the first portion (20) defining a first lasing cavity (29) for emitting electromagnetic radiation at a first wavelength ?1 and the first and second portions (20, 21) together defining a second lasing cavity (31) for emitting electromagnetic radiation at a second wavelength ?2.
Type:
Application
Filed:
September 17, 2013
Publication date:
October 8, 2015
Applicant:
University College Cardiff Consultants, Ltd.
Abstract: The present invention features methods for stimulating clearance of amyloid beta in microglia, decreasing cognitive decline associated with amyloid pathology, and treating Alzheimer's disease by selectively inhibiting the expression or activity of Acyl-CoA:Cholesterol Acyltransferase 1, but not Acyl-CoA:Cholesterol Acyltransferase 2.
Type:
Grant
Filed:
September 11, 2013
Date of Patent:
October 6, 2015
Assignee:
Trustees of Dartmouth College
Inventors:
Ta-Yuan Chang, Catherine C. Y. Chang, Yohei Shibuya, Elena Bryleva, Stephanie Murphy, Maximillian A. Rogers
Abstract: The invention relates to a method of detecting the coincidence of two biomolecular structures in a solid phase sample, said method comprising: (i) providing a first and a second fusion protein, each fusion protein comprising (a) a detection domain, said detection domain comprising a DNA binding domain; said detection domain capable of binding a cognate specific nucleotide sequence in co-operation with a further detection domain; (b) a recognition domain, said recognition domain capable of binding a target biomolecular structure; and (c) a connector domain; said connector domain being fused at one end to the detection domain and being fused at the other end to the recognition domain; wherein at least two of (a), (b) and (c) are heterologous to one another; wherein the recognition domains of said first and said second fusion proteins are capable of binding to first and second biomolecular structures; (ii) contacting the sample with said first and second fusion proteins; (iii) incubating to allow binding; (iv) r
Abstract: Aggregation is a major cause of the misbehavior of proteins. A system for modifying a protein to create a more stable variant is provided. The method involves identifying non-conserved hydrophobic amino acid residues on the surface of a protein, suitable for mutating to more hydrophilic residues (e.g., charged amino acids). Any number of residues on the surface may be changed to create a variant that is more soluble, resistant to aggregation, has a greater ability to re-fold, and/or is more stable under a variety of conditions. The invention also provides GFP, streptavidin, and GST variants with an increased theoretical net charge created by the inventive technology. Kits are also provided for carrying out such modifications on any protein of interest.
Type:
Grant
Filed:
June 1, 2007
Date of Patent:
October 6, 2015
Assignee:
President and Fellows of Harvard College
Inventors:
David R. Liu, Kevin John Phillips, Michael S. Lawrence
Abstract: Techniques are disclosed for providing a duplicate content mode in touch sensitive computing devices. The duplicate content mode can be used to copy content or objects to a target location using a multiple contact point drag and drop gesture. For example, the duplicate content mode may be used to copy files from a first folder to a second folder. In some cases, the duplicate content mode drag and drop gesture is initiated using multiple contact points, such as two or more fingers, but may transition to a smaller number of contact points, such as one finger, once initiated. In some cases, the user may be able to select additional content after initiating the drag and drop gesture. Once the content has been copied to the target location, the user can then share or organize the content to the users liking.
Type:
Grant
Filed:
May 3, 2013
Date of Patent:
October 6, 2015
Assignee:
Barnes & Noble College Booksellers, LLC
Inventors:
Kourtny M. Hicks, Amir Mesguich Havilio
Abstract: The present invention provides for engineered molecular opsonins that may be used to bind biological pathogens or identify subclasses or specific pathogen species for use in devices and systems for treatment and diagnosis of patients with infectious diseases, blood-borne infections or sepsis. An aspect of the invention provides for mannose-binding lectin (MBL), which is an abundant natural serum protein that is part of the innate immune system. The ability of this protein lectin to bind to surface molecules on virtually all classes of biopathogens (viruses, bacteria, fungi, protozoans) make engineered forms of MBL extremely useful in diagnosing and treating infectious diseases and sepsis.
Type:
Grant
Filed:
January 19, 2011
Date of Patent:
October 6, 2015
Assignee:
President and Fellows of Harvard College
Inventors:
Michael Super, Jeffrey Charles Way, Donald E. Ingber
Abstract: The invention provides novel and versatile classes of riboregulators, including inter alia activating and repressing riboregulators, switches, and trigger and sink RNA, and methods of their use for detecting RNAs in a sample such as a well and in modulating protein synthesis and expression.
Type:
Application
Filed:
November 6, 2013
Publication date:
October 1, 2015
Applicants:
President and Fellows of Harvard College, Trustees of Boston University
Inventors:
Alexander A. Green, Peng Yin, James J. Collins
Abstract: The present invention discloses generalizable methods of evolving nucleic acids and proteins utilizing continuous directed evolution. The invention discloses methods of passing a nucleic acid from cell to cell in a desired function-dependent manner. The linkage of the desired function and passage of the nucleic acid from cell to cell allows for continuous selection and mutation of the nucleic acid.
Type:
Application
Filed:
May 5, 2015
Publication date:
October 1, 2015
Applicant:
President and Fellows of Harvard College
Abstract: The present invention generally relates to prostaglandin transport. More specifically, the invention is directed to compounds that inhibit prostaglandin transport and subsequent COX-2 induction, and methods relating thereto.
Type:
Grant
Filed:
July 23, 2012
Date of Patent:
September 29, 2015
Assignees:
Albert Einstein College of Medicine of Yeshiva University, New York University
Inventors:
Victor L. Schuster, Yuling Chi, Young-Tae Chang, Jaeki Min